Reviewer’s report

Title: Effectiveness of Direct-Acting Antiviral Therapy for Hepatitis C in Difficult-to-Treat Patients in a Safety-Net Health System: A Retrospective Cohort Study

Version: 0 Date: 10 Sep 2017

Reviewer: Tracy Swan

Reviewer's report:

This is an excellent, well written and important paper - congratulations to all of you on both the work you've done and this paper describing it. I have a few suggestions:

1) A schematic of the model of care, and description would enhance the paper; you have demonstrated comparable SVR among populations described as "difficult to treat" -- a description of patient flow, or any lessons learned in delivery of care would advance the field.

2) Is this a mistake : "Similarly, rates of SVR were numerically but not significantly higher in patients with health insurance (90% vs. 90%, p=0.98)" ?

3) Could you report on SVR among people with 'the' genotypes, especially G3 - I'm assuming that is why SOF/DAC was used - and perhaps a table with SVR by regimen? Not sure if there is room, but would be interesting to include in supplemental materials.

4) WHO has updated their global estimate to 71 million chronically infected people rather than the 185 million; you may want to change this.

5) What happened with the rest of the patients who were screened- why weren't they treated?

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes
Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review? If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

Not relevant to this manuscript

**Quality of written English**
Please indicate the quality of language in the manuscript:

Acceptable

**Declaration of competing interests**
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organisation that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal